Skip to main content

Volume 3 Supplement 2

30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015)

  • Poster presentation
  • Open access
  • Published:

Natural toll-like receptor agonists in prophylactic vaccines for dendritic cell activation


There is an unmet need for novel and effective treatments for lymphoma, the fifth most common malignancy in the US. In situ vaccination—an immunotherapeutic maneuver involving local irradiation, intratumoral (i.t.) injections of Flt3L and Toll-like receptor (TLR) agonist—has been shown in recent clinical trials (NCT00185965, NCT00880581, NCT00226993) to induce partial and complete remissions in patients with low-grade lymphoma[1]. The strength of anti-tumor response correlates with the potency of immunogenic dendritic cells (DCs) to efficiently uptake and present tumor antigens to T cells[2]. While the latest clinical trial NCT01976585 employs Poly-ICLC—a synthetic TLR3 agonist—to activate DCs, we hypothesize that “natural” TLR agonists (nTLRa) contained within prophylactic vaccines could simultaneously target multiple TLRs and be repurposed as clinical-grade DC activators for the in situ vaccination maneuver[3].


Twenty-four prophylactic vaccines were screened for TLR ligand activity using in vitro assays. DC subsets CD11c+MHC-II+, CD11c+CD11b+, and CD11c+CD103+ were gated for: (i.) activation markers (e.g. CD80, CD86, MHC I, II), (ii.) ability to co-stimulate T cells in the context of TCR activation, as assessed by T cell activation markers (e.g. CD69, intracellular IFNγ), and (iii.) ability of nTLRa-activated DCs to induce T cell proliferation. TLR knock-out cell lines were used for dissecting the mechanistically-distinct properties of each prophylactic vaccine. Best single and combination nTLRa candidates were evaluated with the in situ vaccination maneuver in an in vivo A20 murine lymphoma model.


We identify a combination of vaccines Typhim, BCG-TICE, and MMR that possess the ability to induce high expression of costimulatory molecules on DCs in vitro (Figure 1), as well as co-stimulating in vitro T cell activation and proliferation. DC costimulation of T cell activation and proliferation is highly dependent on the “live” status of several vaccines, including BCG, MMR, Zostavax, suggesting the involvement of other pattern-recognition receptors in addition to TLRs. Cohorts of mice implanted with A20 lymphoma tumors that received i.t. injections of Typhim, BCG, MMR demonstrated slower tumor growth status as compared to the control cohort receiving only Flt3L and local irradiation (Figure 2).

figure 1
figure 2


Prophylactic vaccines contain natural ligands to TLRs and are immediately translatable as sources of clinical-grade stimulators of dendritic cells. Combinations of the best nTLRa candidates display synergistic activation of DCs and in vivo anti-A20 murine lymphoma immunity.


  1. Brody : Journal of Clinical Oncology. 2010, 28: 4324-4332.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Gnjatic : Cancer Journal. 2010, 16: 382-391.

    Article  CAS  Google Scholar 

  3. Schreibelt : Blood. 2010, 116: 564-574.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations


Rights and permissions

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.

The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this licence, visit

The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Peng, P., Hammerich, L. & Brody, J. Natural toll-like receptor agonists in prophylactic vaccines for dendritic cell activation. j. immunotherapy cancer 3 (Suppl 2), P446 (2015).

Download citation

  • Published:

  • DOI: